{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Naltrexone+hydrochloride",
    "query": {
      "intervention": "Naltrexone hydrochloride"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 408,
    "total_pages": 41,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Naltrexone+hydrochloride&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-16T11:31:21.342Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07224087",
      "title": "Development of a MHBC Intervention for Weight Loss and Smoking Cessation for Pre-Bariatric Surgery Patients",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Obesity",
        "Smoking Cessation",
        "Bariatric Surgery Patients"
      ],
      "interventions": [
        {
          "name": "Naltrexone Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Bupropion HCl Extended Release",
          "type": "DRUG"
        },
        {
          "name": "Cognitive-Behavioral Therapy",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BEHAVIORAL"
      ],
      "sponsor": "Medical University of South Carolina",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 20,
      "start_date": "2026-10-01",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-09-09",
      "last_synced_at": "2026-09-16T11:31:21.342Z",
      "location_count": 1,
      "location_summary": "Charleston, South Carolina",
      "locations": [
        {
          "city": "Charleston",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07224087"
    },
    {
      "nct_id": "NCT06500793",
      "title": "Single Dose Study, Pharmacokinetics of Oxycodone and PF614 Co-Administered With Nafamostat (PF614-MPAR-102)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pharmacokinetics",
        "Healthy Volunteer"
      ],
      "interventions": [
        {
          "name": "PF614 capsule",
          "type": "DRUG"
        },
        {
          "name": "Nafamostat Mesylate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ensysce Biosciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 54,
      "start_date": "2024-11-24",
      "completion_date": "2027-04-28",
      "has_results": false,
      "last_update_posted_date": "2026-05-26",
      "last_synced_at": "2026-09-16T11:31:21.342Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06500793"
    },
    {
      "nct_id": "NCT02317744",
      "title": "Treatment of Binge Eating Disorder in Obesity: Naltrexone/ Bupropion Combination Versus Placebo",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Binge Eating Disorder"
      ],
      "interventions": [
        {
          "name": "Naltrexone and bupropion combination",
          "type": "DRUG"
        },
        {
          "name": "Pill Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "21 Years to 65 Years"
      },
      "enrollment_count": 22,
      "start_date": "2014-12",
      "completion_date": "2016-09",
      "has_results": true,
      "last_update_posted_date": "2017-12-22",
      "last_synced_at": "2026-09-16T11:31:21.342Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02317744"
    },
    {
      "nct_id": "NCT00183222",
      "title": "Effectiveness of Naltrexone and/or Ondansetron to Reduce Craving for Alcohol and Drinking",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alcohol Dependence"
      ],
      "interventions": [
        {
          "name": "naltrexone (up to 50 mg/day) for 8 days; ondansetron (0.25 mg twice a day) for 8 days",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Medical University of South Carolina",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "21 Years to 65 Years"
      },
      "enrollment_count": 160,
      "start_date": "2005-05",
      "completion_date": "2005-12",
      "has_results": false,
      "last_update_posted_date": "2010-05-05",
      "last_synced_at": "2026-09-16T11:31:21.342Z",
      "location_count": 1,
      "location_summary": "Charleston, South Carolina",
      "locations": [
        {
          "city": "Charleston",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00183222"
    },
    {
      "nct_id": "NCT00420992",
      "title": "A Study of Embeda (Kadian NT, ALO-01) in Subjects With Pain Due to Osteoarthritis of the Hip or Knee",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Osteoarthritis",
        "Chronic Pain"
      ],
      "interventions": [
        {
          "name": "ALO-01 (Morphine Sulfate Plus Naltrexone Hydrochloride Extended Release)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 547,
      "start_date": "2006-12",
      "completion_date": "2007-11",
      "has_results": true,
      "last_update_posted_date": "2013-09-20",
      "last_synced_at": "2026-09-16T11:31:21.342Z",
      "location_count": 81,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Peoria, Arizona + 69 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00420992"
    },
    {
      "nct_id": "NCT00218530",
      "title": "Effectiveness of Naltrexone and Lofexidine in Treating Detoxified Heroin Addicts - 1",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Heroin Dependence"
      ],
      "interventions": [
        {
          "name": "Lofexidine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute on Drug Abuse (NIDA)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 0,
      "start_date": "2003-03",
      "completion_date": "2004-09",
      "has_results": false,
      "last_update_posted_date": "2017-01-12",
      "last_synced_at": "2026-09-16T11:31:21.342Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00218530"
    },
    {
      "nct_id": "NCT01721070",
      "title": "Effect of Ketoconazole on Sufentanil NanoTab Pharmacokinetics",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pharmacokinetics"
      ],
      "interventions": [
        {
          "name": "Sufentanil NanoTab (SUF NT) 15 mcg",
          "type": "DRUG"
        },
        {
          "name": "Ketoconazole 400 mg, sufentanil NanoTab (SUF NT) 15 mcg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Talphera, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 19,
      "start_date": "2012-11",
      "completion_date": "2012-12",
      "has_results": true,
      "last_update_posted_date": "2016-11-04",
      "last_synced_at": "2026-09-16T11:31:21.342Z",
      "location_count": 1,
      "location_summary": "Lenexa, Kansas",
      "locations": [
        {
          "city": "Lenexa",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01721070"
    },
    {
      "nct_id": "NCT04708327",
      "title": "Single-Blind Study of STAT-205 in Mild COVID-19",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "STAT-205",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cytocom, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2021-12-05",
      "completion_date": "2022-09-30",
      "has_results": false,
      "last_update_posted_date": "2021-12-22",
      "last_synced_at": "2026-09-16T11:31:21.342Z",
      "location_count": 2,
      "location_summary": "Loma Linda, California • Pompano Beach, Florida",
      "locations": [
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Pompano Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04708327"
    },
    {
      "nct_id": "NCT01057862",
      "title": "Investigation of Naltrexone for Pathological Gambling",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pathological Gambling"
      ],
      "interventions": [
        {
          "name": "Naltrexone",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2009-02",
      "completion_date": "2017-01",
      "has_results": true,
      "last_update_posted_date": "2017-10-13",
      "last_synced_at": "2026-09-16T11:31:21.342Z",
      "location_count": 3,
      "location_summary": "Middletown, Connecticut • New Haven, Connecticut",
      "locations": [
        {
          "city": "Middletown",
          "state": "Connecticut"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01057862"
    },
    {
      "nct_id": "NCT02110264",
      "title": "Injectable Pharmacotherapy for Opioid Use Disorders (IPOD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Opioid Use Disorders"
      ],
      "interventions": [
        {
          "name": "XR-NTX",
          "type": "DRUG"
        },
        {
          "name": "XR-NTX+PN",
          "type": "BEHAVIORAL"
        },
        {
          "name": "ETAU",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BEHAVIORAL"
      ],
      "sponsor": "University of California, Los Angeles",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 151,
      "start_date": "2015-06",
      "completion_date": "2019-05",
      "has_results": true,
      "last_update_posted_date": "2020-01-22",
      "last_synced_at": "2026-09-16T11:31:21.342Z",
      "location_count": 1,
      "location_summary": "Albuquerque, New Mexico",
      "locations": [
        {
          "city": "Albuquerque",
          "state": "New Mexico"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02110264"
    }
  ]
}